Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

What Happened: A notable Form 4 filing on Monday with the U.S. Securities and Exchange Commission revealed that Meury, Chief Executive Officer at Incyte, exercised stock options for 0 shares of INCY, ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukemia significantly improves patient outcomes post-transplant, reducing ...

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. Authors: ... Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia. Previous.

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

Graft versus Host Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States ...

Pharmacologic suppression of graft-versus-host disease (GVHD) is critical to the success of hematopoietic stem cell transplantation (HSCT). 1 The use of cyclophosphamide for GVHD prevention has ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

So, we marked another World Sickle Cell Day on Thursday, June 19. But truthfully, what was there to celebrate? I can’t speak ...